Chronic kidney disease is classified into five stages based on how well your kidneys filter waste from the blood, measured by a value called the estimated glomerular filtration rate (eGFR). Stage 1 represents mild kidney damage with normal or high filtration, while stage 5 means the kidneys have lost nearly all function. What makes this staging system more than a simple countdown is that each stage carries distinct health risks, and the line between stable disease and rapid decline depends on factors that many people never learn about until they are well into the later stages.
How the Stages Are Defined
The international standard for staging CKD comes from the KDIGO (Kidney Disease Improving Global Outcomes) guidelines, which use two measurements together: eGFR and albuminuria, a marker of protein leaking into the urine.1JAMA. Glomerular Filtration Rate and Albuminuria for Detection and Staging of Acute and Chronic Kidney Disease in Adults: A Systematic Review The eGFR is expressed in milliliters per minute per 1.73 square meters of body surface area, and the five stages break down as follows:
- Stage 1: eGFR 90 or above with evidence of kidney damage such as protein in the urine or structural abnormalities on imaging.
- Stage 2: eGFR 60–89, again with evidence of damage. Without that evidence, a mildly reduced eGFR alone in an older adult is not necessarily CKD.
- Stage 3a: eGFR 45–59.
- Stage 3b: eGFR 30–44.
- Stage 4: eGFR 15–29.
- Stage 5: eGFR below 15, often called kidney failure.
The albuminuria layer adds a separate axis. Even at the same eGFR, someone spilling large amounts of protein into their urine faces a higher risk of progression and cardiovascular events than someone with little or no protein. This is why two people can both be “stage 3” yet have very different outlooks. A recent cohort study found that urine protein levels were actually a more robust predictor of cognitive decline than eGFR when the two were modeled together, underscoring how albuminuria captures damage that eGFR alone can miss.2JAMA Network Open. Chronic Kidney Disease Severity and Risk of Cognitive Impairment
Stages 1 and 2: Damage Without Symptoms
Most people in stages 1 and 2 feel entirely normal. The kidneys have enough reserve capacity that even with measurable damage, blood tests can look reassuringly close to healthy ranges. This is precisely why CKD in its early phases is so often caught incidentally during routine bloodwork or screening for diabetes and high blood pressure.
What is happening beneath the surface is less reassuring. When some nephrons (the kidney’s filtering units) are lost to disease, the surviving nephrons compensate by working harder, a process called glomerular hyperfiltration. This keeps your overall GFR looking adequate, but the extra pressure inside each remaining nephron gradually damages those units too. The increased glomerular capillary pressure enlarges the filtering structures, stresses specialized cells called podocytes, and promotes protein leakage into the urine, which in turn overloads the downstream tubules.3Oxford Academic. Glomerular hyperfiltration as a therapeutic target for CKD In other words, the kidneys’ own coping mechanism accelerates further damage. This is one reason why early intervention, even when lab values look only slightly off, can change the long-term trajectory.
Stage 3: Where Most People Are Diagnosed
Stage 3 is the point at which CKD most often comes to clinical attention, partly because a GFR below 60 trips automatic flags in many lab reporting systems. It is split into 3a (45–59) and 3b (30–44) because the risks are meaningfully different between them. People in stage 3a may remain stable for years, sometimes decades. Stage 3b is where the pace of complications tends to pick up.
Two complications that typically surface around this stage deserve attention: mineral bone disease and anemia. As GFR falls, the kidneys struggle to keep calcium, phosphorus, parathyroid hormone, and vitamin D in balance. The resulting disturbance, known as CKD-mineral bone disease, weakens bone structure and promotes calcium deposits in blood vessels and soft tissues.4PubMed Central. Mineral bone disorders in chronic kidney disease This is not garden-variety osteoporosis; the bone abnormalities in CKD involve changes in how bone turns over and mineralizes, which makes them harder to treat with standard osteoporosis drugs.
Anemia begins because the kidneys produce less erythropoietin, the hormone that signals the bone marrow to make red blood cells. Iron metabolism also goes haywire. The combination leaves many patients fatigued, short of breath on exertion, and less able to exercise, and the prevalence climbs with each advancing stage.5Pediatric Nephrology. Anemia in Chronic Kidney Disease These complications often develop quietly, which is why regular lab monitoring matters even when you feel fine.
Stages 4 and 5: When Toxins Accumulate
By stage 4, the kidneys can no longer keep up with the body’s waste production. Toxins that healthy kidneys clear continuously begin accumulating in the blood, a condition broadly called uremia. These uremic toxins fall into categories based on their size and how they travel in the bloodstream: some are small and dissolve freely in water, others bind tightly to proteins, and a third group consists of larger “middle molecules.” Each category contributes to organ damage in different ways.6PubMed Central. Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets Patients at this point often experience nausea, loss of appetite, itching, difficulty concentrating, and a metallic taste in the mouth, all signs that the body’s internal chemistry is slipping out of range.
Metabolic acidosis, a state where the blood becomes too acidic, is another hallmark of advanced CKD. Among patients with CKD and elevated potassium, those who also had metabolic acidosis were far more likely to have advanced disease and to require oral sodium bicarbonate therapy.7PubMed Central. Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia Acidosis does more than make you feel lousy; it accelerates muscle wasting, worsens bone disease, and may speed the decline in kidney function itself.
Stage 5, kidney failure, is the threshold at which the body can no longer sustain itself without either dialysis, a transplant, or intensive conservative management. Some people reach stage 5 over decades; others, particularly those with aggressive or poorly controlled disease, arrive within a few years of diagnosis.
Cardiovascular Risk Runs Through Every Stage
If there is one thing about CKD that deserves more public awareness, it is the cardiovascular connection. Heart disease does not wait until the kidneys fail. People with CKD face a significantly elevated risk of heart attacks, strokes, and heart failure well before they ever need dialysis, and cardiovascular death is actually more common than progression to kidney failure in the earlier stages.8PubMed Central. Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health The reasons are layered: high blood pressure damages both kidneys and arteries simultaneously, uremic toxins injure blood vessel walls, and the mineral imbalances of CKD promote calcification of arteries. Managing blood pressure, cholesterol, and blood sugar is not just “kidney care” — it is cardioprotection.
How Accurate Is Your eGFR Number
The eGFR on your lab report is an estimate, and the accuracy of that estimate depends on what it is based on. Most labs calculate eGFR from serum creatinine, a waste product of muscle metabolism. The problem is that creatinine levels are influenced by your muscle mass, diet, and certain medications, so the number can mislead. A very muscular person may appear to have worse kidney function than they do; a frail elderly person may look better than reality.
Adding a second blood test, cystatin C, improves things. Cystatin C is produced at a more constant rate across body types and is less affected by muscle mass. In a large analysis across general-population cohorts, the prevalence of reduced kidney function was higher when estimated by cystatin C than by creatinine alone, suggesting that creatinine-based estimates miss a meaningful number of people whose kidneys are actually impaired.9PubMed Central. Cystatin C versus Creatinine in Determining Risk Based on Kidney Function Using both markers together produced the best risk classification: people whose eGFR moved to a higher category when cystatin C was added genuinely had lower risks of death and kidney failure, while those reclassified downward truly faced higher risks.
Research comparing the two approaches confirms that the combined creatinine-cystatin C equation achieves the highest accuracy and the best correlation with directly measured GFR.10PubMed. Comparison of bias and accuracy using cystatin C and creatinine in CKD-EPI equations for GFR estimation If you have borderline results or if treatment decisions hinge on your stage, asking about a cystatin C test is reasonable. It is increasingly covered by insurance and can resolve the ambiguity that a creatinine-only test sometimes leaves.
Slowing Progression With Medication and Diet
CKD is not a one-way conveyor belt toward dialysis. The rate of decline varies enormously, and several interventions have solid evidence behind them for putting the brakes on.
SGLT2 inhibitors, a class of drugs originally developed for type 2 diabetes, have become a cornerstone of CKD treatment regardless of whether diabetes is present. They work by reducing pressure inside the kidney’s filtering units through a mechanism tied to how the kidney handles sodium and glucose, independent of blood sugar lowering.11PubMed Central. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations A meta-analysis found that SGLT2 inhibitors were effective in delaying CKD progression and lowering mortality, though they do require monitoring for certain side effects.12PubMed Central. Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis If you have CKD and are not on one of these drugs, it is worth a conversation with your nephrologist about whether you are a candidate.
Dietary protein restriction is another lever, though it requires more nuance. A secondary analysis of the landmark MDRD trial found that for patients with a GFR below 25, each reduction in protein intake was associated with a slower rate of GFR decline, potentially prolonging the time to kidney failure by about 41%.13PubMed. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study However, the ideal protein target depends on the stage and situation. Expert recommendations suggest keeping intake below about 1.0 grams per kilogram of ideal body weight per day for early-stage, non-proteinuric CKD, and dropping to 0.6–0.8 grams per kilogram for patients with eGFR below 45 or significant proteinuria.14PubMed Central. Dietary Protein Intake and Chronic Kidney Disease Sticking to these targets is genuinely difficult and works best with a renal dietitian’s help, because cutting protein too aggressively risks malnutrition, especially in older adults.
When Kidneys Fail: Dialysis, Transplant, or Conservative Care
Once CKD reaches stage 5, the question of renal replacement therapy becomes urgent. The three main paths are hemodialysis, peritoneal dialysis, and kidney transplantation. A systematic review comparing outcomes found that transplant recipients had significantly lower mortality than dialysis patients, with the survival advantage growing over time. The risk of cardiovascular events also dropped after transplantation, and quality of life was substantially better.15PubMed. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes After a successful transplant, reported quality of life can approach that of the general population in the short term, though it tends to taper over the long run as the demands of immunosuppressive medication and the risk of graft issues accumulate.16Nephrology Dialysis Transplantation. Mapping health-related quality of life after kidney transplantation by group comparisons: a systematic review
Not everyone is a transplant candidate, however, and not everyone wants dialysis. Conservative kidney management (CKM) is a structured approach that focuses on symptom control, quality of life, and comfort without dialysis. In the general population with stage 5 CKD, dialysis is associated with longer survival. But among people aged 80 and older, or elderly patients with multiple other serious illnesses, the survival benefit of dialysis tends to disappear.17PubMed Central. Does conservative kidney management offer a quantity or quality of life benefit compared to dialysis? A systematic review For these patients, dialysis can mean frequent hospital visits, vascular access complications, and a treatment burden that erodes the remaining quality time, while conservative management may offer comparable survival with fewer interventions and less time spent in hospital.18PubMed Central. Dialysis versus conservative kidney management in older adults: why one size does not fit all This is a deeply individual decision, and the point is that it should be a decision, not a default.
When Acute Injury Hits Chronically Damaged Kidneys
One underappreciated danger is the overlap between acute kidney injury (AKI) and CKD. An episode of AKI, whether triggered by dehydration, a medication reaction, infection, or surgery, can leave lasting damage even after blood values appear to recover. The repair process in injured kidney tubules sometimes goes wrong: cells fail to fully re-differentiate, and signaling pathways stay abnormally active, driving ongoing inflammation and scarring in the surrounding tissue.19PubMed Central. Acute kidney injury: a springboard for progression in chronic kidney disease AKI and CKD also have a bidirectional relationship. Having CKD makes you more vulnerable to acute injury, and each AKI episode can ratchet chronic damage forward, pushing someone from one stage to the next in a way that might not have happened without the acute event.20PubMed. Transition from acute kidney injury to chronic kidney disease: mechanisms, models, and biomarkers
This has practical implications. If you are living with CKD, even early-stage, being vigilant about hydration, cautious with over-the-counter painkillers (particularly NSAIDs), and proactive about discussing kidney safety with your doctor before any new medication or planned procedure can help you avoid an AKI episode that permanently bumps you down a stage.
CKD in Children
CKD in children is a different clinical entity in several respects. The causes are more often congenital or structural (abnormalities of the urinary tract, inherited conditions) rather than the diabetes and hypertension that drive adult CKD. Beyond the kidney-specific complications shared with adults, children with CKD face growth disturbances and neurodevelopmental consequences. A scoping review found evidence of altered brain structure and function in children with CKD, including reduced brain volume and compromised structural integrity, with associated deficits in both cognitive and motor domains.21PubMed. Neurodevelopmental outcomes in children with chronic kidney disease: a scoping review These effects make early detection and aggressive management even more critical in the pediatric population, since the window for normal brain development and linear growth is finite.
Who Gets CKD and Why Income Matters
CKD is not distributed evenly across the population. Socioeconomic status plays a surprisingly large role that goes beyond whether someone can afford a doctor’s visit. In an analysis of over 14,000 U.S. adults, poverty (defined as income below twice the federal poverty level) was associated with roughly 35% greater odds of early-stage protein leakage in the urine. A separate study of more than 22,500 adults found that a household income below $20,000 per year, compared with above $75,000, more than doubled the odds of heavy albuminuria, with the relationship being even stronger among Black participants.22PubMed Central. Socioeconomic Disparities in Chronic Kidney Disease These disparities reflect a tangle of factors: limited access to primary care and preventive screening, higher rates of uncontrolled diabetes and hypertension in lower-income communities, environmental exposures, and the chronic physiological stress of poverty itself.
Predicting Who Will Progress Quickly
One of the frustrations of CKD care is that two patients at the same stage can have wildly different trajectories. Some stay stable for a decade; others lose kidney function rapidly. Current staging captures a snapshot, not a trajectory. Researchers have been hunting for blood-based biomarkers that could improve prediction. In a study of patients with type 2 diabetes and CKD, a panel of 14 serum biomarkers, added on top of standard clinical data like eGFR and albuminuria, substantially improved the ability to predict rapid progression. The biomarkers included markers of kidney tubule injury, metabolic stress, and vascular damage.23PubMed. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes These panels are not yet routine in clinical practice, but they represent a shift toward a future where CKD staging might incorporate not just where your kidneys are but where they are headed.
CKD and Cognitive Decline
A connection that patients rarely hear about is the link between worsening kidney function and the brain. A cohort study found that more advanced CKD stage was prospectively associated with a higher incidence of cognitive impairment, and the relationship held even after accounting for age, blood pressure, and other confounders.24JAMA Network Open. Chronic Kidney Disease Severity and Risk of Cognitive Impairment The mechanism likely involves uremic toxins crossing the blood-brain barrier, vascular damage from the same processes that harm the kidneys, and chronic inflammation. For patients and families, this means that changes in memory, attention, or decision-making in someone with CKD should not automatically be chalked up to aging. They may be a signal that kidney management needs intensifying, and they have implications for treatment adherence, since a patient struggling cognitively may have trouble keeping up with the complex medication regimens and dietary restrictions that CKD demands.